Management

He founded Zoltan Kiss CanCureLab biotechnological company in 2021 for which now he serves as the President and CEO. This family-owned company is based, for the most part, on his research showing that a human protein can effectively prevent the loss of skeletal muscle proteins in various non-cachectic and cachectic mouse tumor models and in aging mice with relevance to similar human conditions.

*About the Founder: Zoltan Kiss, Ph.D., had an extensive academic research career before founding and leading several biotechnological companies. Until 2004, he was Professor and Section Leader at the University of Minnesota. Prior to that, he was a Senior Investigator at the National Cancer Institute (4 years) and held several faculty positions in the U.S. and Europe. Dr. Kiss holds a Ph.D. degree, and his research so far has resulted in 114 peer-reviewed articles and 27 issued international patents as well as 5 filed patent applications on the treatments of cancer cachexia, wounds, bone marrow protection, and various metabolic disorders including specific treatment of excess visceral fat. Most recently, Dr. Kiss has been focusing on (1) studying how ZKCPr1 prevents or reduces muscle loss in various animal tumor models and aging mice, and (b) finding effective interventions to normalize excess visceral obesity while determining the nature of relationships between visceral fat as well as various metabolic disorders, cancer, and longevity in appropriate mouse models using a unique experimental approach, free of confounding factors, which gives more reliable results than human observational studies.